Pricing Log in Create free account
Saturday 17 October 2026 Export PACB’s income statement to Excel — free account

Pacific Biosciences of California, Inc.

PACB Healthcare Medical Devices

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.73 0.23 −11.73%
Market cap
$609.2M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
−6.04
Beneish M
−5.14
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.37
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — 3 3 1 — — — 1 — 1
Insider Ownership 8.51%

Capital & Financial Ratios $m

Market Cap 609.23
Revenue 159.27
Net Income (131.39)
Free Cash Flow (80.48)
Net Debt 407.43
Current Ratio 4.92 (at or above 1.5: strong)
Debt/Equity (19.40) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (3.54) (negative: loss-making)
P/S ratio 3.37
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 74.10% (at or above 15%: strong)
Next Y EPS Growth 5.00%
Next Y revenue growth (0.82%) (below 0%: weak)
Next 5Y EPS Growth 41.41% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.9×, against a ten-year median of 7.1×; over the ten years it ranged from 1.8× in 2018 to 67.4× in 2021.
P/S against its own 10 years 22.93%
10-year low 10-year high
EV/Sales against its own 10 years 40.99%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 632 391 280 237
Receivables 37 28 35 31
Inventory 57 59 49 61
Other — — — —
742 496 375 339
2023 2024 2025 Q'26
Payables 15 17 21 19
ST’ Debt — — — —
Other 8 3 2 2
95 66 73 69

Compound Annual Growth %

10y 5y 3y
Sales 5.60% 15.19% 7.64%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (23.06%) (56.30%) (78.82%)

Revenue $m

Mar Jun Sep Dec Year
’26 37 39 — — —
’25 37 40 38 45 160
’24 39 36 40 39 154
’23 39 48 56 58 201
’22 33 35 32 27 128
’21 29 31 35 36 131
’20 16 17 19 27 79
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (45) (36) — — —
’25 (44) (29) (19) (19) (111)
’24 (76) (54) (45) (31) (206)
’23 (95) (42) (65) (58) (259)
’22 (79) (61) (63) (61) (263)
’21 (23) (16) (41) (32) (111)
’20 75 (24) (18) (14) 20
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (39) — — —
’25 (50) (30) (19) (20) (119)
’24 (80) (56) (45) (32) (212)
’23 (98) (44) (66) (60) (268)
’22 (83) (65) (67) (66) (280)
’21 (24) (17) (42) (35) (117)
’20 75 (24) (18) (14) 18
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.03) (0.14) — — —
’25 (1.44) (0.14) (0.13) (0.13) (1.82)
’24 (0.29) (0.64) (0.22) (0.49) (1.07)
’23 (0.36) (0.28) (0.26) (0.31) (1.21)
’22 (0.37) (0.32) (0.34) (0.37) (1.40)
’21 (0.45) (0.21) 0.08 (0.31) (0.89)
’20 0.01 (0.15) (0.14) 0.37 0.17
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 3.76 2.51 2.02 4.37 2.20 18.26 3.85 5.74 1.16 0.85

Analyst estimates 2026–2028

Powerpack
High 13.98 5.74 7.84 7.50 29.73 53.69 21.01 14.55 9.99 2.73
People
People Employees 438 456 401 404 412 728 769 796 575 485
Revenue/emp, $m 0.21 0.20 0.20 0.22 0.19 0.18 0.17 0.25 0.27 0.33
Income, $m
Income, $m Revenue 91 93 79 91 79 131 128 201 154 160
Gross margin, % 48.68 37.08 31.92 38.04 41.28 45.10 38.22 26.32 24.21 28.61
EBT (74) (92) (103) (84) 29 (275) (314) (318) (310) (546)
EBT margin, % (81.99) (98.63) (130.44) (92.57) 37.27 (210.61) (244.92) (158.67) (200.98) (341.28)
Net income (74) (92) (103) (84) 29 (181) (314) (307) (310) (546)
Depreciation 5 10 7 10 9 16 17 14 225 397
Per share, $
Per share, $ Revenue 1.02 0.88 0.58 0.60 0.48 0.64 0.57 0.79 0.56 0.53
Earnings (0.83) (0.87) (0.76) (0.55) 0.18 (0.89) (1.40) (1.21) (1.12) (1.82)
Cash flow (0.76) (0.64) (0.49) (0.51) 0.12 (0.54) (1.17) (1.02) (0.75) (0.37)
Capex (0.09) (0.10) (0.01) (0.02) (0.01) (0.03) (0.08) (0.03) (0.02) (0.03)
Free cash flow (0.85) (0.74) (0.51) (0.53) 0.11 (0.57) (1.25) (1.06) (0.77) (0.40)
Book value 0.95 0.81 0.84 0.36 2.03 3.87 2.51 2.77 1.85 0.02
Shares, m 89 106 135 153 165 204 225 254 274 300
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 216.17 0.00 0.00 0.00 0.00 0.00
P/S 4.28 3.15 12.71 8.63 54.31 32.00 13.90 12.13 3.26 3.51
P/B 4.59 3.42 8.76 14.28 12.77 5.28 3.17 3.47 0.99 104.86
EV/Sales 3.67 2.63 11.60 8.54 50.74 30.86 14.86 13.43 4.93 5.79
EV/FCF (4.37) (3.15) (13.36) (9.57) 216.82 (34.39) (6.81) (10.05) (3.58) (7.79)
Cash, $m
Cash, $m Operating cash flow (68) (68) (66) (78) 20 (111) (263) (259) (206) (111)
Capex (8) (10) (2) (3) (1) (6) (17) (9) (6) (8)
Free cash flow (76) (78) (68) (81) 18 (117) (280) (268) (212) (119)
Balance, $m
Balance, $m Working capital 75 73 105 32 317 1,029 589 647 429 302
Total debt 16 14 15 42 38 896 897 892 647 645
Net debt (56) (49) (88) (7) (282) (149) 124 261 257 366
Shareholders’ equity 85 86 114 55 335 791 563 701 507 5
Returns, %
Returns, % ROA (55.30) (65.39) (65.25) (52.87) 10.46 (14.97) (16.65) (17.46) (20.61) (53.45)
ROIC (154.63) (152.21) (239.39) (132.25) (121.17) (20.48) (27.95) (21.73) (38.83) (93.25)
ROE (94.02) (107.97) (102.48) (99.58) 15.06 (32.18) (46.42) (48.53) (51.30) (213.45)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Pacific Biosciences of California, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CTKB Cytek Biosciences, Inc. $703.2M — (loss-making) — (loss-making) +5.57% (above 0%: growing) n/m +42.50% (above 0%: growing) 58.87% (23.68%) Compare
PACB Pacific Biosciences of California, Inc. $609.2M — (loss-making) — (loss-making) −1.91% (below 0%: shrinking) n/m −30.97% (below 0%: shrinking) 32.40% (114.36%)
KIDS OrthoPediatrics Corp. $589.3M — (loss-making) — (loss-making) +15.43% (above 0%: growing) n/m +77.59% (above 0%: growing) 74.27% (5.77%) Compare
TCMD Tactile Systems Technology, Inc. $527.6M 20.5× 22.7× +8.61% (above 0%: growing) +142.86% (above 0%: growing) −86.53% (below 0%: shrinking) 76.25% 7.97% Compare
SSII SS Innovations International, Inc. $517.2M — (loss-making) — (loss-making) +39.39% (above 0%: growing) n/m −16.62% (below 0%: shrinking) 50.94% (16.29%) Compare
DCTH Delcath Systems, Inc. $513.9M 1,408× — (loss-making) +20.60% (above 0%: growing) −12.50% (below 0%: shrinking) −24.45% (below 0%: shrinking) 89.75% 8.22% Compare
MASS 908 Devices Inc. $491.5M — (loss-making) — (loss-making) +23.31% (above 0%: growing) n/m +150.95% (above 0%: growing) 51.90% (79.69%) Compare
SGHT Sight Sciences, Inc. $484.8M — (loss-making) — (loss-making) +19.55% (above 0%: growing) n/m +26.71% (above 0%: growing) 91.39% (16.62%) Compare
BWAY Brainsway Ltd. Sponsored ADR $475.8M 24.8× — (loss-making) +35.43% (above 0%: growing) +40.00% (above 0%: growing) −51.68% (below 0%: shrinking) 74.62% 13.98% Compare
Median of peers $515.6M 24.8× — +20.07% +40.00% +5.05% 74.45% (11.03%)

All 149 Medical Devices stocks →

Pacific Biosciences of California, Inc. (PACB) key facts

  • Concern: Pacific Biosciences of California, Inc. reported a net loss of $546.4 million, or a loss of $1.82 per share, for fiscal 2025.
  • Strength: Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024.
  • Pacific Biosciences of California, Inc. (PACB) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PACB traded at $1.73, a market capitalization of $609.2 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 3.4× sales.
  • Return on equity was −213.5% and debt-to-equity -19.40.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −6.04 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Pacific Biosciences of California, Inc. (PACB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/PACB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com